The use of small molecule APP translation blockers will be described in the following sections to list their common properties as therapeutic agents that can remediate the consequences of either too much APP expression as in DS patients (Section 1) [3] or too little APP expression (Section 2). The gene discussed is APP; the disease is Dravet syndrome.